Clinical biochemical and haematological parameters during long-term continuous infusion of aljathesin were studied in twelve neurosurgical patients who did not have multiple organ failure. Significant changes which were possibly caused by aljathesin were an alteration of blood film morphology, an elevation of plasma triglyceride and a reduction in plasma high-density lipids.
MATERIALS AND METHOD Twelve consecutive neurosurgical patients requiring sedation for both intermittent positive pressure ventilation (IPPV) and reduction of raised intracranial pressure (ICP) were studied. Details of the patients are given in Table 1 . No patient had a known contraindication to sedation with alfathesin (i.e. history of allergy, 6 asthma 7 or epilepsy8). During the infusioQ. no c ment developed adverse effects su'ch as anaphylaxis 6 ,7 or convulsions 8 which would warrant stopping the infusion. The intracranial pressure was measured in all patients using a subarachnoid bolt (Richmond Screw~.
Intermittent intravenous (IV) doses of pancuronium 1-2 mg and phenoperidine 0.5-1 mg were also used to facilitate ventilation. The use of alfathesin, however, reduced the requirements for these drugs. Other drugs used included high-dose steroids (dexamethasone IV 4 mg 6 hourly), ranitidine (IV 50 mg 12 hourly), boluses of mannitol (IV 20-30 g) when indicated and prophylactic antibiotics for the duration of Anaesthesia and Intensive Care, Vol. 12 (*Coagulation profiles were measured on these patients) the ICP monitoring. Parenteral feeding was commenced in five patients but supplementation with intralipid was avoided.
Undiluted alfathesin was filtered from 5 ml ampoules into 250 ml bags. Each bag of alfathesin was infused through a central venous catheter using an IMED volumetric infusion pump. The infusion was commenced at 5 mllhour with 2-5 mllhour increments until satisfactory sedation and control of ICP was achieved.
Blood for biochemical and haematological estimations was obtained from a peripheral vein. Serum urea, creatmme, electrolytes, haemoglobin, white cell count, platelets and plasma viscosity were measured daily. Serum bilirubin, alkaline phosphatase, aspartate aminotransferase, total protein, albumin, plasma cholesterol, triglycerides and highdensity lipids were measured every third day. Coagulation profiles (prothrombin time, partial thromboplastin time, thrombin clotting time and plasma fibrinogen) were measured every third day on five patients (Table 1) . Details of laboratory techniques are given in Table 2 . Baseline values were obtained prior to commencing the infusion and the mean preinfusion values were calculated. Mean values were also calculated from values immediately after ceasing the infusion. The mean preinfusion and post-infusion values were statistically analysed using a Student's t-test.
RESULTS
The alfathesin was infused over an average of 7.8 days with a mean total dose of 1823 ml and a mean daily dose of 232 ml ( Table 1) . The results are presented in Table 3 . Significant changes outside the normal range were found in haemoglobin, serum albumin, plasma triglycerides, high-density lipids (HDL), viscosity and fibrinogen. There was, however, no correlation between the changes in these parameters and either the duration or total dose of alfathesin infused. A consistent finding was the alteration of the blood film morphology, both macroscopically and microscopically.
During preparation of the slide, smooth spreading of the blood was impossible and the resulting film had an irregular, oily appearance ( Figure 1 ). Microscopically there was marked variation in the thickness of the blood film with irregular distribution of white cells and platelets, and some distortion of the red cell morphology.
DISCUSSION
Alfathesin is a steroidal anaesthetic agent composed of 0.9010 alphaxolone, 0.3070 alphadolone acetate, 0.25010 sodium chloride in water and 20% cremophor EL (polyethoxylated castor oil). Alphaxolone is the major active constituent having twice the activity of alphadolone acetate, which is added only to improve solubility. In man alphaxolone has a plasma half-life of 1.6 minutes, is cleared rapidly by the liver and excreted in the bile. ID Cremophor EL is the solvent and is produced by reacting ethylene oxide with castor oil, the major products being polyethoxylated esters of ricinoleic acid triglyceride. 11 In rats cremophor EL has a plasma half-life of 22 hours and is hydrolysed by pancreatic and liver enzymes before being excreted in the urine. II The inactive metabolite has a half-life of 13 minutes indicating that the enzymatic hydrolysis is the rate-limiting step in elimination. II There is little information about the effects of prolonged infusion of alfathesin, especially after large doses. However, polyethoxylated castor oil (PECO) has been shown to produce an abnormal lipoprotein electrophoretic pattern in man. 12 . 14 The abnormal pattern consists of a densely staining pre-[3 band and an absence or marked reduction in the Cl' band. This may be the result of "delipidation" of the high-density fraction. 12 cholesterol. The Cl' band is composed of HDL. Rats treated with PEeO showed amorphous myxomatous degeneration and focal calcification in the walls of their thoracic aortas. 12 ,13 There have also been reports of abnormal liver function during infusion of alfathesin. I ,2,15 However, in most cases this has been readily explicable on other clinical grounds. Blunnie et al. found some derangement of liver enzymes in patients receiving infusion of many intravenous anaesthetic agents, including alfathesin. 16 More recently it has been suggested that sedation of critically ill patients with continuous infusion of etomidate, alfathesin and possibly other intravenous anaesthetic agents, may be associated with an increased mortality and morbidity .17, 18 However, this remains controversial. 19, 20 Possible mechanisms cited include suppression of adrenocortical function or cell-mediated immunity. 16, 21 Concern has also been expressed on the possible cumulative effects on cremophor. 18 Stewart et al., who studied 20 critically ill patients during long-term continuous infusion of alfathesin, also noted the abnormal lipoprotein electrophoretic pattern. However, they could not attribute any other changes to alfathesin, and concluded that alfathesin by infusion is a safe and effective technique for long-term sedation. 2 Nonetheless, many of their patients had multiple organ failure and it was difficult to evaluate the effect of alfathesin on their biochemical and haematological parameters. Furthermore, no details were given about overall mortality and morbidity.
In the present study, the 12 patients had only intracranial pathology, and no other organ failure. During the infusion there were significant changes in six parameters (Table 2) . However, only the changes in plasma lipids would not normally be expected. The fall in serum albumin was consistent with the metabolic response to stress and is commonly seen in intensive care patients. 22 A small preand post-infusion difference in mean haemoglobin could be expected from blood loss associated with each patient's initial injury, venous sampling or subsequent surgery. Plasma fibrinogen levels may rise in response to injury, stress or infection. 23 The increase in fibrinogen and other acute phase proteins may result in an increased plasma viscosity, and this viscosity change can be used as a mark of disease activity. 23, 24 It is interesting to note that the observed rise in plasma viscosity in the present study is in sharp contrast to previous reports of a reduction in plasma viscosity following anaesthetic induction doses of alfathesin. 25 ,26 The increase in plasma triglycerides and reduction in plasma HDL is in keeping with the previous reported abnormal lipoprotein electrophoretic pattern. The changes in blood film morphology may be associated with an alteration of blood fluidity and microcirculatory flow, and further investigation of this important area is warranted.
The results of the present study suggest that alfathesin by infusion has no significant shortterm effect on routine clinical biochemical and haematological parameters, with the exception of the alteration in plasma lipids and blood film morphology. However, no comment can be made on possible subclinical or latent toxicity. Alfathesin is· a convenient and useful agent to provide sedation and to control ICP in headinjured patients. Nevertheless, the use of the drug in this manner should be limited until more is known about the significance of the observed changes, and a more definitive assessment of the effect of alfathesin on adrenocortical and immune function is available.
